Cancer drug sales power up Kelun-Biotech’s profit engine
The firm made more money from precision oncology treatments than from licensing deals in the first half, after gaining insurance coverage for its core drugs in China Key Takeaways: The…
Precision cancer drugs show promise for Kelun-Biotech
The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
BRIEF: Kelun-Biotech raises $250 million through share placement
Innovative cancer drug company Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. (6990.HK) announced on Thursday it plans to sell 5.92 million shares through a placement, representing 2.54% of its enlarged share capital.…
No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
- Mega licensing deal lifts 3SBio profits but core sales slip
-
Alphamab seals $2.2 billion licensing deal with AI biotech
9966.HK
- Insilico revenue soars above $100 million on AI drug partnerships
- A healthy return: drug spin-off nets Keymed up to $320 million
- Cancer screening company faces tough IPO test as market cools
